Business context and reporting period
Entity clarification: Although the request identifies Elutia Inc., the supplied Form 10-Q is filed by Aziyo Biologics, Inc. (Nasdaq: AZYO); it does not provide financial information for Elutia. The report covers the quarter and six months ended June 30, 2023, and was filed August 14, 2023.
Aziyo is a commercial-stage regenerative medicine company selling products across device protection, women’s health, orthobiologics and cardiovascular markets, as well as contract-manufactured products.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $10.3M | $12.6M | $23.3M | $24.1M |
| Gross profit | $1.0M | $4.9M | $7.3M | $9.2M |
| Gross margin | 9.5% | 38.8% | 31.3% | 38.0% |
| Operating loss | $9.1M | $8.2M | $15.5M | $15.1M |
| Net loss | $10.6M | $9.4M | $18.6M | $17.5M |
| Net loss per share | $0.65 | $0.69 | $1.15 | $1.29 |
For the six months, net cash used in operating activities was $7.6M, investing activities used $0.3M, and financing activities provided $0.1M. Cash was $9.3M at June 30, down from $17.0M at December 31, 2022. Current assets of $36.1M were below current liabilities of $42.9M. Stockholders’ deficit was $22.1M.
Long-term debt had a $24.9M net carrying value at June 30; the company reported approximately $25.8M of SWK term-loan principal outstanding before unamortized discount and financing costs. The loan’s weighted-average interest rate was 13.0% in Q2. The revenue interest obligation was $16.0M in total, including $10.4M current and $5.6M long-term.
Material changes versus the prior comparable period
- Q2 sales fell 18.5%; six-month sales fell 3.3%. Orthobiologics sales declined 39.1% in Q2, while women’s health sales rose 31.6%.
- Q2 gross margin fell to 9.5%, reflecting a $3.0M revenue reversal/product returns reserve and a $2.0M VBM inventory write-off. Together, the VBM-related impact was $5.0M. The six-month gross margin also declined, to 31.3% from 38.0%.
- Operating expenses declined overall, including lower sales and marketing, general and administrative, and research and development costs. FiberCel litigation costs increased to $1.3M in Q2 and $3.2M for the first half.
- Interest expense increased to $1.5M in Q2 and $3.1M for the first half, partly due to the SWK facility’s higher interest cost compared with the prior-year debt.
Outlook, risks and unusual items
- Going concern: Management states substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It expects continued cash outflows and cannot determine when, or whether, it will become profitable. Potential responses include raising capital, restructuring the revenue interest obligation, or pursuing asset sales or other transactions; success is not assured.
- VBM matter: In July 2023, the company recalled one lot of viable bone matrix and withdrew specified VBM products after tuberculosis infections were reported in two patients treated with product from the lot. At least five of 36 patients implanted with product from that lot had findings consistent with tuberculosis, according to the CDC. The company is working with the FDA and CDC. No VBM-related claims had been filed as of the report; management considered material claims reasonably possible but not probable or estimable, and recorded no liability for them.
- FiberCel litigation: The company reported 27 settled cases for approximately $7.5M, of which 26 had been paid for $7.3M. It accrued a total estimated liability of $14.5M for the litigation and recorded $8.9M in related reimbursement receivables. It could not estimate potential losses above the accrued amount.
- Commercial and regulatory risks: Surgalign entered Chapter 11 in June; its contract is not being assumed by the buyer of relevant assets, making future related sales uncertain. Surgalign represented about 10% of revenue in the periods presented, and $0.8M of its $1.1M gross receivable was reserved. CanGaroo RM received an FDA “Not Substantially Equivalent” letter in March 2023; the company aimed to respond to outstanding questions during 2023, with clearance uncertain.
- Debt and listing: The SWK loan is secured by company assets and includes revenue and minimum-liquidity covenants. The company reported covenant compliance at June 30. Nasdaq had notified the company of a market-value listing deficiency, with an initial compliance deadline of October 31, 2023.
- Other items: LeMaitre Vascular received exclusive U.S. distribution rights for specified cardiovascular products under a three-year agreement, with an option to acquire the product line. Sientra received certain non-exclusive U.S. distribution rights for SimpliDerm. Management reported no formal financial guidance in the supplied filing text.
Important facts for investors to verify
- Confirm the filing applies to Aziyo Biologics, not Elutia Inc., before using these figures.
- Monitor cash runway, financing or restructuring actions, and the company’s ability to meet the SWK facility’s liquidity and revenue covenants.
- Track the VBM investigation, product availability, any claims or litigation, and potential financial exposure beyond recorded adjustments.
- Assess FiberCel settlement progress, the adequacy and collectability of the $8.9M reimbursement receivable, and potential losses above the accrued liability.
- Follow CanGaroo RM’s FDA pathway, the Surgalign relationship’s revenue impact, and Nasdaq listing compliance.